Inositols in PCOS
- PMID: 33260918
- PMCID: PMC7729761
- DOI: 10.3390/molecules25235566
Inositols in PCOS
Abstract
(1) Background: Myoinositol (MI) and D-chiro-inositol (DCI) are involved in a number of biochemical pathways within oocytes having a role in oocyte maturation, fertilization, implantation, and post-implantation development. Both inositols have a role in insulin signaling and hormonal synthesis in the ovaries. (2) Methods: Literature search (with key words: inositols, myo-inositol, d-chiro-inositol, PCOS) was done in PubMed until Sept. 2020 and 197 articles were identified, of which 47 were of clinical trials (35 randomized controlled trials). (3) Results: Many studies have demonstrated that in patients with polycystic ovarian syndrome (PCOS) MI treatment improved ovarian function and fertility, decreased the severity of hyperandrogenism including acne and hirsutism, positively affected metabolic aspects, and modulated various hormonal parameters deeply involved in the reproductive axis function and ovulation. Thus treating with MI has become a novel method to ameliorate PCOS symptoms, improve spontaneous ovulation, or induce ovulation. The current review is focused on the effects of MI and DCI alone or in combination with other agents on the pathological features of PCOS with focus on insulin resistance and adverse metabolic outcomes. (4) Conclusions: The available clinical data suggest that MI, DCI, and their combination in physiological ratio 40:1 with or without other compound could be beneficial for improving metabolic, hormonal, and reproductive aspects of PCOS.
Keywords: PCOS; inositols; insulin resistance.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Inositol in Polycystic Ovary Syndrome: Restoring Fertility through a Pathophysiology-Based Approach.Trends Endocrinol Metab. 2018 Nov;29(11):768-780. doi: 10.1016/j.tem.2018.09.001. Epub 2018 Sep 27. Trends Endocrinol Metab. 2018. PMID: 30270194 Review.
-
PCOS and Inositols - Advances and Lessons We are Learning. A Narrative Review.Drug Des Devel Ther. 2025 May 21;19:4183-4199. doi: 10.2147/DDDT.S524718. eCollection 2025. Drug Des Devel Ther. 2025. PMID: 40420946 Free PMC article. Review.
-
The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios.Eur Rev Med Pharmacol Sci. 2019 Jun;23(12):5512-5521. doi: 10.26355/eurrev_201906_18223. Eur Rev Med Pharmacol Sci. 2019. PMID: 31298405 Clinical Trial.
-
Inositols' Importance in the Improvement of the Endocrine-Metabolic Profile in PCOS.Int J Mol Sci. 2019 Nov 18;20(22):5787. doi: 10.3390/ijms20225787. Int J Mol Sci. 2019. PMID: 31752081 Free PMC article. Review.
-
Experts' opinion on inositols in treating polycystic ovary syndrome and non-insulin dependent diabetes mellitus: a further help for human reproduction and beyond.Expert Opin Drug Metab Toxicol. 2020 Mar;16(3):255-274. doi: 10.1080/17425255.2020.1737675. Epub 2020 Mar 19. Expert Opin Drug Metab Toxicol. 2020. PMID: 32129111 Review.
Cited by
-
Inositols: From Established Knowledge to Novel Approaches.Int J Mol Sci. 2021 Sep 30;22(19):10575. doi: 10.3390/ijms221910575. Int J Mol Sci. 2021. PMID: 34638926 Free PMC article. Review.
-
Novel Chemical and Biological Insights of Inositol Derivatives in Mediterranean Plants.Molecules. 2022 Feb 24;27(5):1525. doi: 10.3390/molecules27051525. Molecules. 2022. PMID: 35268625 Free PMC article. Review.
-
A Narrative Review of Current Understanding of the Pathophysiology of Polycystic Ovary Syndrome: Focus on Plausible Relevance of Vitamin D.Int J Mol Sci. 2021 May 5;22(9):4905. doi: 10.3390/ijms22094905. Int J Mol Sci. 2021. PMID: 34063169 Free PMC article. Review.
-
Kelulut Honey Ameliorates Oestrus Cycle, Hormonal Profiles, and Oxidative Stress in Letrozole-Induced Polycystic Ovary Syndrome Rats.Antioxidants (Basel). 2022 Sep 22;11(10):1879. doi: 10.3390/antiox11101879. Antioxidants (Basel). 2022. PMID: 36290602 Free PMC article.
-
A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?Int J Mol Sci. 2023 Mar 25;24(7):6213. doi: 10.3390/ijms24076213. Int J Mol Sci. 2023. PMID: 37047186 Free PMC article.
References
-
- Azziz R., Carmina E., Dewailly D., Diamanti-Kardarakis E., Escobar-Morreale H.F., Futterweit W., Janssen O.E., Legro R.S., Norman R.J., Taylor A.E., et al. Positions statement: Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: An Androgen Excess Society guideline. J. Clin. Endocrinol. Metab. 2006;91:4237–4245. doi: 10.1210/jc.2006-0178. - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical